Cardiology

Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries

Retrieved on: 
Wednesday, April 3, 2024
Cardiology, Health, Media, Diabetes, Communications, Philanthropy, Consumer, Foundation, Online, Hypertension, Country, Merck, Subject, Prize money, Multimedia, Pharmaceutical industry

Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.

Key Points: 
  • Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.
  • View the full release here: https://www.businesswire.com/news/home/20240327222745/en/
    Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries (Graphic: Business Wire)
    The theme of the awards is to promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension.
  • Senator, Dr. Rasha Kelej, CEO of Merck Foundation emphasized, “Media plays a critical role in enhancing awareness in the public on critical health issues.
  • Merck Foundation has also launched these awards for African and Asian countries.

Nourish Raises $35M Series A to Expand Access to Registered Dietitians

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Software, Telemedicine, Virtual Medicine, Oncology, Apps, Applications, Technology, Artificial Intelligence, Fitness & Nutrition, Health Insurance, Cardiology, Health, Diabetes, Blood pressure, Partner, BoxGroup, Growth, Y Combinator, Disease, TCV, Patient, Conditional sentence, Weight loss, Food, Thrive Capital, Index Ventures, Cancer, NPS, Insurance, Eating disorder, Adolescence, Diet, RDS, Access, Prediabetes, Medicine

Nourish , a telenutrition platform that connects people to registered dietitians covered by insurance, announced today that it has raised $35 million in Series A funding.

Key Points: 
  • Nourish , a telenutrition platform that connects people to registered dietitians covered by insurance, announced today that it has raised $35 million in Series A funding.
  • With $44M in total funding since its founding in 2021, Nourish plans to accelerate development of its digital platform for patients and providers, expand its network of registered dietitians (RDs), and deepen its strategic partnerships with insurance companies.
  • “Our goal is to create a win-win-win for patients, providers, and payers,” said Sam Perkins, co-founder, President and COO of Nourish.
  • “Nourish aims to help tens of millions of Americans by providing access to a dietitian and the incredible nutritional education, accountability, and care that they provide.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, March 26, 2024
Hospitals, Health, Cardiology, Medical Devices, Atrial fibrillation, Conference, Interest, LAA

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 23rd Annual Needham Virtual Healthcare Conference.
  • AtriCure’s management is scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 1:30 p.m. Eastern Standard Time.
  • Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at https://ir.atricure.com .

egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board

Retrieved on: 
Tuesday, March 26, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Practice Management, Managed Care, Health, Artificial Intelligence, Bernard Marcus, International Society, Coronary artery disease, Partnership, George Washington University, Patient, Research, Cardiac catheterization, NYU, Treasurer, MD, Society, Amoroso, Medical school, Vinod, Physician, Pharmaceutical industry

egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .

Key Points: 
  • egnite, Inc. , a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD, to its Medical Advisory Board .
  • His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.
  • "We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board," said Joel Portice, president and CEO of egnite.
  • The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.

Viz.ai and Medtronic Collaborate to Improve Post-Acute Stroke Patient Care in the United States

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Cardiology, Software, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, Stroke, Conductance quantum, Communication, Atrial fibrillation, Risk, Patient, AI, Arrhythmia, Medtronic, MD, Trial of the century, Viz, Service

Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.

Key Points: 
  • Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.
  • For stroke patients who are at risk of atrial fibrillation (“AF”) post-stroke and may need additional cardiac monitoring, stroke care teams in the U.S. will have the opportunity to use the Viz Connect™ solution, a software tool that automates the communication across disciplines, including neurology and cardiology.
  • Recent clinical study results indicate that both community hospitals and academic centers are in need of stronger, standardized care pathways between neurology and cardiology to ensure that stroke patients receive guideline-directed therapy.
  • According to the DiVERT Stroke clinical study, only 16% of stroke patients from community hospitals and 34% of patients at academic centers received a cardiology consult.1
    “Through our collaboration with Medtronic, we have the opportunity to bring cardiology and neurology closer together by using software tools that help facilitate stroke patient care,” said Chris Mansi, MD, CEO and co-founder at Viz.ai.

KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Oncology, Other Science, Mental Health, Research, Hospitals, Genetics, Science, Clinical Trials, Cardiology, Principal, Brain, Policy, White House Fellows, ALS, Auburn House, Business, Lewy body dementias, Foreign Policy, Georgetown University, Harvard Kennedy School, Public policy, Virology, Bristol Myers Squibb, MBBS, Autophagy, House, IND, MBA, Iraq War, St. Lawrence University, B cell, Louisiana House of Representatives, MCAS, Hematology, Mast cell activation syndrome, Representative, Bluebird bio

KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.

Key Points: 
  • KeifeRx, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative and immune diseases, announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
  • KeifeRx is currently conducting optimizing and IND-enabling studies involving four separate formulations – KFRX03, KFRX04, KFRX05, and KFRX06 – with patent life through 2037.
  • Ms. Finger, the Principal at Auburn House Consulting, LLC, serves on the Board of ADMA Biologics, Inc. and is an Advisor at Quantile Health.
  • She previously held Board positions at Decibel Therapeutics, Vascular Biogenics and served as Chief Commercial Officer at Bluebird Bio.

Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials

Retrieved on: 
Thursday, March 28, 2024
FDA, Health, Technology, Clinical Trials, Artificial Intelligence, Cardiology, Diagnosis, Coronary ischemia, Patient, Myocardial perfusion imaging, Journal, Ischemia, MD, American College, CCTA, Stenosis, Atherosclerosis, SPECT, Medical device

The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.

Key Points: 
  • The study describes the validation of Cleerly's artificial intelligence-guided quantitative coronary CT angiography (AI-QCT) ISCHEMIA technology for diagnostic accuracy and prognostic risk stratification.
  • For patients with an abnormal Cleerly AI-QCT ISCHEMIA finding, a positive result was associated with an approximately 7-fold increase of adverse cardiovascular events during an 8-year follow-up.
  • Collectively, this study shows that Cleerly AI-QCT ISCHEMIA, when used in conjunction with Cleerly LABS, can provide a 3-in-1 approach for the assessment of atherosclerosis, stenosis and ischemia.
  • These study results come after Cleerly announced that its Cleerly ISCHEMIA software device is billable using the new Category I CPT® code 75580.

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

Retrieved on: 
Tuesday, March 26, 2024
General Health, FDA, Medical Devices, Health, Cardiology, Corporation, CERS, Food, Cerus Corporation, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately.
  • This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year.
  • All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories are now eligible for this six-month extension.
  • This shelf-life extension applies to all sizes of INTERCEPT Platelet Processing Sets currently available in the U.S.
    “We are pleased with this successful and timely outcome to our regulatory filing with the FDA to re-establish a longer shelf life for INTERCEPT Platelet Processing Sets in the U.S.,” said Vivek Jayaraman, Cerus’ chief operating officer.

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

Retrieved on: 
Tuesday, March 26, 2024
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, MSD, FC, Exercise, Breakthrough therapy, Blood, Risk, Patient, Orthostatic hypertension, MRK, World Health Organization, Heart, WHO, Multimedia, PAH, Food, Pharmaceutical industry

“The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.

Key Points: 
  • “The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association.
  • In the WINREVAIR treatment group, the placebo-adjusted median increase in 6MWD was 41 meters (95% CI: 28, 54; p
  • The median treatment difference in PVR between WINREVAIR and placebo was -235 dynes*sec/cm5 (95% CI: -288, -181; p
  • The median treatment difference in NT-proBNP between WINREVAIR and placebo was -442 pg/mL (95% CI: -574, -310; p